Varithena is a drug owned by Provensis Ltd. It is protected by 16 US drug patents filed from 2013 to 2016. Out of these, 2 drug patents are active and 14 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 12, 2032. Details of Varithena's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7731986 | Therapeutic foam |
Nov, 2024
(a month ago) |
Expired
|
| US8734833 | Therapeutic foam |
May, 2020
(4 years ago) |
Expired
|
| US8323677 | Therapeutic foam |
May, 2020
(4 years ago) |
Expired
|
| US7604185 | Generation of therapeutic microfoam |
May, 2020
(4 years ago) |
Expired
|
| USRE40640 | Injectable microfoam containing a sclerosing agent |
Oct, 2016
(8 years ago) |
Expired
|
| USRE38919 | Injectable microfoam containing a sclerosing agent |
Oct, 2014
(10 years ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9480652 | Aerosol valve |
May, 2032
(7 years from now) | Active |
| US7814943 | Apparatus and method for dispensing foam |
Nov, 2027
(2 years from now) | Active |
| US8122917 | Apparatus and method for dispensing foam |
Sep, 2024
(3 months ago) |
Expired
|
| US6846412 | Combination filter assembly |
Jul, 2022
(2 years ago) |
Expired
|
| US7025290 | Generation of therapeutic microfoam |
May, 2020
(4 years ago) |
Expired
|
| US7842283 | Generation of therapeutic microfoam |
May, 2020
(4 years ago) |
Expired
|
| US6942165 | Generation of therapeutic microfoam |
May, 2020
(4 years ago) |
Expired
|
| US6572873 | Generation of therapeutic microfoam |
May, 2020
(4 years ago) |
Expired
|
| US7357336 | Generation of therapeutic microfoam |
May, 2020
(4 years ago) |
Expired
|
| US7842282 | Generation of therapeutic microfoam |
May, 2020
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Varithena's patents.
Latest Legal Activities on Varithena's Patents
Given below is the list of recent legal activities going on the following patents of Varithena.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed Critical | 24 Jun, 2024 | US9480652 |
| Expire Patent Critical | 01 Apr, 2024 | US8122917 |
| Maintenance Fee Reminder Mailed Critical | 16 Oct, 2023 | US8122917 |
| Interim Patent Term Extension Granted Critical | 28 Feb, 2023 | US7357336 |
| Expire Patent Critical | 04 Jul, 2022 | US8734833 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 May, 2022 | US7842283 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 May, 2022 | US7842282 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Apr, 2022 | US7814943 |
| Interim Patent Term Extension Granted Critical | 07 Mar, 2022 | US7357336 |
| Maintenance Fee Reminder Mailed Critical | 17 Jan, 2022 | US8734833 |
Several oppositions have been filed on Varithena's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Varithena's generic, the next section provides detailed information on ongoing and past EP oppositions related to Varithena patents.
Varithena's Oppositions Filed in EPO
Varithena has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 20, 2010, by Chemische Fabrik Kreussler & Co. Gmbh. This opposition was filed on patent number EP04798566A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP04798550A | Apr, 2018 | CHEMISCHE FABRIK KREUSSLER & CO. GMBH | Opposition rejected |
| EP04798564A | Sep, 2010 | CHEMISCHE FABRIK KREUSSLER & CO. GMBH | Patent maintained as amended |
| EP04798564A | Sep, 2010 | STRAWMAN LIMITED | Patent maintained as amended |
| EP04798566A | Apr, 2010 | CHEMISCHE FABRIK KREUSSLER & CO. GMBH | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Varithena is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Varithena's family patents as well as insights into ongoing legal events on those patents.
Varithena's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Varithena's generic launch date based on the expiry of its last outstanding patent is estimated to be May 12, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Varithena Generics:
There are no approved generic versions for Varithena as of now.
About Varithena
Varithena is a drug owned by Provensis Ltd. It is used for treating varicose veins. Varithena uses Polidocanol as an active ingredient. Varithena was launched by Provensis in 2017.
Approval Date:
Varithena was approved by FDA for market use on 21 December, 2017.
Active Ingredient:
Varithena uses Polidocanol as the active ingredient. Check out other Drugs and Companies using Polidocanol ingredient
Treatment:
Varithena is used for treating varicose veins.
Dosage:
Varithena is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 180MG/18ML (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |